TKAI Tokai Pharmaceuticals Inc

INVESTOR ALERT: Investigation Into Tokai Pharmaceuticals IPO Announced by Holzer & Holzer LLC

ATLANTA--(BUSINESS WIRE)--

Holzer & Holzer is investigating whether Tokai Pharmaceuticals, Inc. (“Tokai” or the “Company”) (NASDAQ: TKAI) issued false and misleading statements to investors in connection with its September 18, 2014 initial public offering (the “IPO”).

If you purchased Tokai common stock before March 17, 2015 and suffered a loss on that investment, you are encouraged to contact Corey D. Holzer, Esq. at [email protected] or via toll-free telephone at (888) 508-6832, to discuss your legal rights.

Holzer & Holzer, LLC is an Atlanta, Georgia law firm that dedicates its practice to vigorous representation of shareholders and investors in litigation nationwide, including shareholder class action and derivative litigation. More information about the firm is available through its website, www.holzerlaw.com and upon request from the firm. Holzer & Holzer, LLC has paid for the dissemination of this promotional communication, and Corey D. Holzer is the attorney responsible for its content.

EN
24/10/2016

Underlying

TKAITokai Pharmaceuticals Inc

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Tokai Pharmaceuticals Inc

 PRESS RELEASE
Free
TKAI Tokai Pharmaceu...

Tokai Pharmaceuticals and Otic Pharma Enter into Share Purchase Agreem...

BOSTON, Mass., IRVINE, Calif., & REHOVOT, Israel--(BUSINESS WIRE)-- Tokai Pharmaceuticals Inc. (NASDAQ:TKAI) and Otic Pharma Ltd., a privately-held, clinical-stage pharmaceutical company focusing on the development and commercialization of products for disorders of the ear, nose, and throat (ENT), today announced that the two companies, together with the shareholders of Otic Pharma, have entered into a definitive share purchase agreement under which the shareholders of Otic Pharma will become the majority owners of Tokai. The...

December 22, 2016 1 EN
 PRESS RELEASE
Free
TKAI Tokai Pharmaceu...

INVESTOR ALERT: Investigation Into Tokai Pharmaceuticals IPO Announced...

ATLANTA--(BUSINESS WIRE)-- Holzer & Holzer is investigating whether Tokai Pharmaceuticals, Inc. (“Tokai” or the “Company”) (NASDAQ: TKAI) issued false and misleading statements to investors in connection with its September 18, 2014 initial public offering (the “IPO”). If you purchased Tokai common stock before March 17, 2015 and suffered a loss on that investment, you are encouraged to contact Corey D. Holzer, Esq. at [email protected] or via toll-free telephone at (888) 508-6832, to discuss your legal rights. ...

October 24, 2016 1 EN
 PRESS RELEASE
Free
TKAI Tokai Pharmaceu...

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Toka...

NEW YORK--(BUSINESS WIRE)-- The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired securities of Tokai Pharmaceuticals, Inc. (NASDAQGM: TKAI) between June 24, 2015 through July 25, 2016. You are hereby notified that a securities class action has been commenced in the USDC for the Southern District of New York. If you purchased or otherwise acquired Tokai securities between June 24, 2015 and July 25, 2016, your rights may be affected by this ac...

September 19, 2016 1 EN
 PRESS RELEASE
Free
TKAI Tokai Pharmaceu...

TKAI INVESTOR ALERT: The Law Offices of Vincent Wong Reminds Investors...

NEW YORK--(BUSINESS WIRE)-- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Southern District of New York on behalf of investors who purchased Tokai Pharmaceuticals, Inc. (NASDAQGM: TKAI) securities between June 24, 2015 and July 25, 2016. Click here to learn about the case: http://www.wongesq.com/pslra/tokai-pharmaceuticals-inc. There is no cost or obligation to you. According to the complaint, throughout the Class Period, Defendants issued false and/or mis...

September 13, 2016 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch